Extravascular Hemolysis, Paroxysmal Nocturnal Hemoglobinuria, PNH
Conditions
Keywords
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis, Ravulizumab, Eculizumab, Danicopan
Brief summary
The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).
Interventions
DRUGDanicopan
Participants will receive danicopan on a weight-based dosing regimen.
Sponsors
AstraZeneca
Alexion Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of PNH. * CS-EVH defined by: Anemia: Hgb ≤ 11.0 g/dL, and absolute reticulocyte count ≥ 100 × 109/L * Treated with ravulizumab or eculizumab for at least 12 weeks immediately preceding Day 1, the dose received should be stable during this period, and there should be no anticipated changes in dosage or interval during the first 12 weeks of this study. * all participants must be vaccinated against meningococcal infection from serogroups A, C, W, and Y and serogroup B within 3 years prior to, or at least 14 days prior to Day 1 * vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae
Exclusion criteria
* Platelet count \< 30000/μL or there is a need for platelet transfusions. * ANC \< 500/μL. * Clinically significant laboratory abnormalities related to liver function, including: * ALT \> 2 × ULN or ALT \> 3 × ULN for participants with documented liver iron overload defined by serum ferritin values ≥ 500 ng/mL. * Direct bilirubin \> 2 × ULN, unless, in the Investigator's opinion, is due to hemolysis or Gilbert's syndrome based on medical history. * Current evidence of biliary cholestasis. * Known aplastic anemia or other bone marrow failure that requires HSCT or other therapies, including anti-thymocyte globulin and immunosuppressants unless the dosage of immunosuppressant has been stable for at least 12 weeks before Day 1 and is expected to remain stable through Week 12. * History of a major organ transplant (eg, heart, lung, kidney, liver) or HSCT. * Known or suspected complement deficiency. * Active bacterial or viral infection, a body temperature \> 38°C on 2 consecutive daily measures, evidence of other infection, or history of any febrile illness within 14 days prior to first study intervention administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in Hemoglobin (Hgb) Concentration at Week 12 | Baseline, Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Transfusion Avoidance Through Weeks 12 and 24 | Weeks 12 and 24 |
| Change From Baseline in Absolute Reticulocyte Count at Weeks 12 and 24 | Baseline, Weeks 12 and 24 |
| Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 |
| Change from Baseline in Pediatric Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 12 and 24 | Baseline, Weeks 12 and 24 |
| Maximum Plasma Concentration (Cmax) of Danicopan | Day 1 up to Week 12 |
| Change from Baseline in Hgb Concentration at Week 24 | Baseline, Week 24 |
| Change from Baseline in Serum Alternative Pathway (AP) Activity | Baseline up to Week 64 |
| Change from Baseline in Plasma Bb Concentrations | Baseline up to Week 64 |
| Acceptability and Palatability Questionnaire Score | Week 2 |
Countries
Canada, France, United Kingdom
Contacts
Primary ContactAlexion Pharmaceuticals, Inc. (Sponsor)
Outcome results
None listed